Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial. Lung Cancer 2022;170:133-140.
PMID: 35777160